Drug profile · INN
olodaterol hydrochloride
STRIVERDI RESPIMAT
olodaterol hydrochloride (STRIVERDI RESPIMAT) is a beta-2 adrenergic receptor agonist. Route of administration: inhalation. Current US regulatory status: approved.
Drug details — olodaterol hydrochloride
- US status
- approved
- Class
- —
- Route
- INHALATION
- Patents
- 0
- Programs
- 0
- Data quality
- 0.84
Quick answer
olodaterol hydrochloride (STRIVERDI RESPIMAT) is a beta-2 adrenergic receptor agonist. Route of administration: inhalation. Current US regulatory status: approved.
Key facts
Mechanism of action
Beta-2 adrenergic receptor agonist
Primary target: Beta-2 adrenergic receptor
Approval history
| Authority | Status | Date |
|---|---|---|
| FDA | approved | — |
Related & competitor drugs
Frequently asked questions
What is olodaterol hydrochloride?
olodaterol hydrochloride (STRIVERDI RESPIMAT) is a beta-2 adrenergic receptor agonist. Route of administration: inhalation. Current US regulatory status: approved.
What is the brand name for olodaterol hydrochloride?
STRIVERDI RESPIMAT is a marketed brand name for olodaterol hydrochloride. Check FDA Drugs@FDA for the current US label holder and prescribing information.
What is the US approval status of olodaterol hydrochloride?
olodaterol hydrochloride has approved status in the United States according to our Drugs@FDA-derived records. Verify on the official FDA label before clinical or commercial decisions.